Teladoc (TDOC) Tops Q1 EPS by 1c

Teladoc (NYSE: TDOC) reported Q1 EPS of ($0.43), $0.01 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $128.6 million versus the consensus estimate of $128.08 million.

“Our first quarter 2019 delivered excellent results across all key financial and operational metrics and set a very positive tone for the year. The strong revenue and visit momentum during the quarter underscores the accelerating pace of adoption across our portfolio of clinical services and diversification of our business,” said Jason Gorevic, chief executive officer, Teladoc Health. “As we exit the quarter with a robust pipeline, continued international expansion and favorable Medicare Advantage regulation, I am more confident than ever that we are uniquely positioned to capitalize on the enormous global market opportunity for virtual care.”

GUIDANCE:

Teladoc sees Q2 2019 EPS of ($0.42)-($0.44), versus the consensus of ($0.40). Teladoc sees Q2 2019 revenue of $128-131 million, versus the consensus of $130 million.

Teladoc sees FY2019 EPS of ($1.56)-($1.66), versus the consensus of ($1.54). Teladoc sees FY2019 revenue of $535-545 million, versus the consensus of $541.73 million.

For earnings history and earnings-related data on Teladoc (TDOC) click here.

You May Also Be Interested In

• Zscaler shares slip following conservative annual billings guidance
• Anavex Life Sciences (AVXL) Tops Q4 EPS by 3c
• Elbit Systems (ESLT) Tops Q3 EPS by 21c